Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Jeffrey Bacha, Dennis Brown, James Geller, Javier Oesterheld, Patrick Thompson, Aerang Kim, Meghann McManus, Sarath Kanekal, Markos Leggas, Lorena Lopez, Neil Sankar, Noymi Yam, Lars Wagner

Cancer Res (2025) 85 (8_Supplement_2): LB266.

https://doi.org/10.1158/1538-7445.AM2025-LB266

Published: 25 April 2025

View articletitled, Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Journal Articles

Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma

Rajesh Yetirajam, Srijan Acharya, Kumar Kuldeep Niloy, Yasuda Kazuto, Jamie Horn, Thomas Prisinzano, Jon S. Thorson, Oleg Tsodikov, Jurgen Rohr, Markos Leggas

Cancer Res (2025) 85 (8_Supplement_1): 4360.

https://doi.org/10.1158/1538-7445.AM2025-4360

Published: 21 April 2025

View articletitled, Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma

Journal Articles

Abstract CT058: A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

James Geller, Patrick Thompson, Javier Oesterheld, Aerang Kim, Meghann McManus, Jeffrey Bacha, Dennis M. Brown, Markos Leggas, Sarath Kanekal, Neil Sankar, Lorena Lopez, Noymi Yam, Lars M. Wagner

Cancer Res (2024) 84 (7_Supplement): CT058.

https://doi.org/10.1158/1538-7445.AM2024-CT058

Published: 05 April 2024

View articletitled, Abstract CT058: A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Journal Articles

Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Jeffrey Bacha, Dennis Brown, Sarath Kanekal, Neil Sankar, Lorena Lopez, Noymi Yam, Lars Wagner, James Geller, Markos Leggas, Patrick Thompson, Javier Osterheld

Cancer Res (2023) 83 (8_Supplement): CT135.

https://doi.org/10.1158/1538-7445.AM2023-CT135

Published: 14 April 2023

View articletitled, Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Journal Articles

Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs

Markos Leggas, Ambika Dudhate, Jurgen Rohr

Cancer Res (2022) 82 (12_Supplement): 1851.

https://doi.org/10.1158/1538-7445.AM2022-1851

Published: 15 June 2022

View articletitled, Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs

Journal Articles

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

James Geller, Patrick Thompson, Javier Oesterheld, Dennis M. Brown, Jeffrey Bacha, Sarath Kanekal, Lorena Lopez, Markos Leggas, Neil Sankar, Noymi Yam, Lars M. Wagner

Cancer Res (2022) 82 (12_Supplement): CT256.

https://doi.org/10.1158/1538-7445.AM2022-CT256

Published: 15 June 2022

View articletitled, Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Journal Articles

Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors

Markos Leggas, Joseph Eckenrode, Yang Liu, Abhisek Mandal, Reiya Hayden, Oleg Tsodikov, Jon Thorson, Jurgen Rorh

Cancer Res (2020) 80 (14_Supplement): A41.

https://doi.org/10.1158/1538-7445.PEDCA19-A41

Published: 15 July 2020

View articletitled, Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors

Journal Articles

Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding

Reiya C. Hayden, Caixia Hou, Prithiba Mitra, Abhisek Mandal, Jurgen Rohr, Jon Thorson, Oleg Tsodikov, Markos Leggas

Cancer Res (2019) 79 (13_Supplement): 2954.

https://doi.org/10.1158/1538-7445.AM2019-2954

Published: 01 July 2019

View articletitled, Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding

Journal Articles

Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting

Joseph Eckenrode, Jamie Horn, Jhong-Min Chen, Jurgen Rohr, Markos Leggas

Cancer Res (2015) 75 (15_Supplement): 2628.

https://doi.org/10.1158/1538-7445.AM2015-2628

Published: 01 August 2015

View articletitled, Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting

Journal Articles

Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients

Tamer Ahmed, John Hayslip, Markos Leggas

Cancer Res (2012) 72 (8_Supplement): 3778.

https://doi.org/10.1158/1538-7445.AM2012-3778

Published: 15 April 2012

View articletitled, Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients

Journal Articles

Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin

Eleftheria Tsakalozou, Dianna Howard, Markos Leggas

Cancer Res (2011) 71 (8_Supplement): 3547.

https://doi.org/10.1158/1538-7445.AM2011-3547

Published: 15 April 2011

View articletitled, Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin

Journal Articles

Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution

Kazumasa Takenaka, Jessica A. Morgan, George L. Scheffer, Masashi Adachi, Clinton F. Stewart, Daxi Sun, Markos Leggas, Karin F.K. Ejendal, Christine A. Hrycyna, John D. Schuetz

Cancer Res (2007) 67 (14): 6965–6972.

https://doi.org/10.1158/0008-5472.CAN-06-4720

Published: 17 July 2007

View articletitled, Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution

Includes: Supplementary data

Journal Articles

Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo

Markos Leggas, John C. Panetta, Yanli Zhuang, John D. Schuetz, Brad Johnston, Feng Bai, Brian Sorrentino, Sheng Zhou, Peter J. Houghton, Clinton F. Stewart

Cancer Res (2006) 66 (9): 4802–4807.

https://doi.org/10.1158/0008-5472.CAN-05-2915

Published: 01 May 2006

View articletitled, Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo

Journal Articles

Functional interaction between Mrp4 (abcc4) and Bcrp (abcg2) as revealed by the single and double-knockout mouse

Kazumasa Takenaka, Jessica Morgan, Masashi Adachi, Daxi Sun, Clinton Stewart, Markos Leggas, Karin F Ejendal, Christine A Hrycyna, John D Schuetz

Cancer Res (2006) 66 (8_Supplement): 144.

Published: 15 April 2006

View articletitled, Functional interaction between Mrp4 (abcc4) and Bcrp (abcg2) as revealed by the single and double-knockout mouse

Journal Articles

Comparative pharmacokinetics in mice of the novel camptothecin analog DB-67 administered in diluted cremophor/ethanol or a supersaturated solution stabilized by a chemically-modified cyclodextrin.

Markos Leggas, Jamie Horn, Sherri Jordan, Michael J. Roberts, Bradley D. Anderson

Cancer Res (2006) 66 (8_Supplement): 1302.

Published: 15 April 2006

View articletitled, Comparative pharmacokinetics in mice of the novel camptothecin analog DB-67 administered in diluted cremophor/ethanol or a supersaturated solution stabilized by a chemically-modified cyclodextrin.

Journal Articles

Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues

Markos Leggas, Rodica P. Bunaciu, Michael J. Roberts, Guoqing Du, Jatinder Lamba, George L. Scheffer, Clinton F. Stewart, John D. Schuetz

Cancer Res (2006) 66 (8_Supplement): 141.

Published: 15 April 2006

View articletitled, Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues

Journal Articles

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Clinton F. Stewart, Markos Leggas, John D. Schuetz, John C. Panetta, Pamela J. Cheshire, Jennifer Peterson, Najat Daw, Jesse J. Jenkins, III, Richard Gilbertson, Glen S. Germain, Franklin C. Harwood, Peter J. Houghton

Cancer Res (2004) 64 (20): 7491–7499.

https://doi.org/10.1158/0008-5472.CAN-04-0096

Published: 15 October 2004

View articletitled, Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Journal Articles

Gefitinib (’Iressa’, ZD1839) is a BCRP and MDR1 inhibitor.

Markos Leggas, John D. Schuetz, John C. Panetta, Brad Johnston, Feng Bai, Sheng Zhou, Brian Sorrentino, Christopher M. Waters, Peter J. Houghton, Clinton F. Stewart

Cancer Res (2004) 64 (7_Supplement): 568.

Published: 01 April 2004

View articletitled, Gefitinib (’Iressa’, ZD1839) is a BCRP and MDR1 inhibitor.

Journal Articles

Multidrug resistance protein 4 (Mrp4) is expressed at the blood-cerebrospinal and blood-brain barriers and restricts topotecan brain penetration

Markos Leggas, Masashi Adachi, Daxi Sun, Guoqing Du, Kelly E. Mercer, John C. Panetta, Yanli Zhuang, George L. Scheffer, Rik J. Scheper, Peter Wielinga, Piet Borst, Clinton F. Stewart, John D. Schuetz

Cancer Res (2004) 64 (7_Supplement): 115–116.

Published: 01 April 2004

View articletitled, Multidrug resistance protein 4 (Mrp4) is expressed at the blood-cerebrospinal and blood-brain barriers and restricts topotecan brain penetration

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma

Abstract CT058: A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors

Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding

Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting

Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients

Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin

Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution

Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo

Functional interaction between Mrp4 (abcc4) and Bcrp (abcg2) as revealed by the single and double-knockout mouse

Comparative pharmacokinetics in mice of the novel camptothecin analog DB-67 administered in diluted cremophor/ethanol or a supersaturated solution stabilized by a chemically-modified cyclodextrin.

Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Gefitinib (’Iressa’, ZD1839) is a BCRP and MDR1 inhibitor.

Multidrug resistance protein 4 (Mrp4) is expressed at the blood-cerebrospinal and blood-brain barriers and restricts topotecan brain penetration

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only